Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Teramana Cancer Center - Steubenville
mi
from
Steubenville, OH
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Teramana Cancer Center - Steubenville
mi
from
Steubenville, OH
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Beaver
mi
from
Beaver, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Beaver
mi
from
Beaver, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg
mi
from
Greensburg, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Arnold Palmer Pavilion - Greensburg
mi
from
Greensburg, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Oakbrook Commons - Greensburg
mi
from
Greensburg, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Oakbrook Commons - Greensburg
mi
from
Greensburg, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Oakbrook Commons
mi
from
Greensburg, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Oakbrook Commons
mi
from
Greensburg, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - John P. Murtha Pavilion - Johnstown
mi
from
Johnstown, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - John P. Murtha Pavilion - Johnstown
mi
from
Johnstown, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group
mi
from
Moon Township, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Sewickley Medical Oncology/Hematology Group
mi
from
Moon Township, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center -Mt. Pleasant
mi
from
Mt. Pleasant, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center -Mt. Pleasant
mi
from
Mt. Pleasant, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Presbyterian -Radiation Oncology
mi
from
Pittsburgh, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Presbyterian -Radiation Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center -Delafield Rd.
mi
from
Pittsburgh, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center -Delafield Rd.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology
mi
from
Pittsburgh, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
Hillman Cancer Center: University of Pittsburgh Cancer Institute / UPMC Department of Radiology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center -Drake
mi
from
Pittsburgh, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center -Drake
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Uniontown
mi
from
Uniontown, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Uniontown
mi
from
Uniontown, PA
Click here to add this to my saved trials
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated:  1/6/2016
UPMC Cancer Center - Washington
mi
from
Washington, PA
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies
Status: Enrolling
Updated: 1/6/2016
UPMC Cancer Center - Washington
mi
from
Washington, PA
Click here to add this to my saved trials
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)
Status: Enrolling
Updated:  1/6/2016
University of Chicago
mi
from
Chicago, IL
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ
A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)
Status: Enrolling
Updated: 1/6/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer
Status: Enrolling
Updated:  1/6/2016
Yale University
mi
from
New Haven, CT
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer
Status: Enrolling
Updated: 1/6/2016
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
St. Louis, MO
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Germantown, TN
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated:  1/6/2016
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Status: Enrolling
Updated: 1/6/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
RAD001 in Recurrent Endometrial Cancer Patients
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Enrolling
Updated:  1/6/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
RAD001 in Recurrent Endometrial Cancer Patients
A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer
Status: Enrolling
Updated: 1/6/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Status: Enrolling
Updated:  1/7/2016
Mount Sinai Hospital
mi
from
New York, NY
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
Status: Enrolling
Updated: 1/7/2016
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Baylor College of Medicine
mi
from
Houston, TX
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Orange County
mi
from
Orange, CA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Childrens National Medical Center
mi
from
Washington,
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Columbia University Medical Center
mi
from
New York, NY
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Oregon Health and Science University
mi
from
Portland, OR
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Saint Jude Childrens Research Hospital
mi
from
Memphis, TN
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Saint Jude Childrens Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Seattle Children's Hospital
mi
from
Seattle, WA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
University of Minnesota Cancer Center-Fairview
mi
from
Minneapolis, MN
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
University of Minnesota Cancer Center-Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
University of California San Francisco Medical Center-Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  1/7/2016
Washington University School of Medicine
mi
from
St. Louis, MO
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 1/7/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices
Assessing the Impact of Low-Touch Devices on Medication Adherence
Status: Enrolling
Updated:  1/7/2016
CVS Health
mi
from
Woonsocket, RI
Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices
Assessing the Impact of Low-Touch Devices on Medication Adherence
Status: Enrolling
Updated: 1/7/2016
CVS Health
mi
from
Woonsocket, RI
Click here to add this to my saved trials
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
Paced Breathing for Hot Flashes: A Randomized Phase II Study
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
Paced Breathing for Hot Flashes: A Randomized Phase II Study
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/7/2016
Mayo Clinic Florida
mi
from
Jacksonville, FL
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/7/2016
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer
Status: Enrolling
Updated:  1/7/2016
The Mayo Clinic
mi
from
Rochester, MN
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer
Status: Enrolling
Updated: 1/7/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  1/7/2016
The Mayo Clinic
mi
from
Rochester, MN
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 1/7/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials